ClinicalTrials.gg
CompletedNCT00647907Updated May 16, 2011

A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections

A Phase 4 interventional study of Voriconazole in Candidiasis, Cryptococcosis and Aspergillosis, sponsored by Pfizer. Completed at 4 sites in Taiwan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-05-16.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Candidiasis by Pfizer — none open to participants now, none under way, none of them phase 3. Candidiasis · Pfizer.

Enrollment
11th of 11
7 · median 41
Started
2003
with 1 other
Phase 4
2 of 15
none open now
Registered
9th of 15
by date

Among the 15 studies in Candidiasis by Pfizer, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2003, is one of 2 in phase 4, and was the 9th registered.

Candidiasis

132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.

Browse Candidiasis studies →

Open to participants now

None of the 15 studies in Candidiasis by Pfizer is open now. The open studies under Candidiasis, anywhere →

Who these studies take

Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Candidiasis by Pfizer as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections

03

Conditions studied

  • Candidiasis
  • Cryptococcosis
  • Aspergillosis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemic or invasive fungal infection
  • Infection caused by organism for which there is no current treatment or infection with evidence of failure and/or intolerance to treatment with approved antifungal agents

Exclusion criteria

Exclusion Criteria:

  • Liver function test abnormalities
  • Renal disease
  • Fungal infections not considered to be invasive or systemic
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    A

    Drug: Voriconazole

Interventions

  • Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.

06

What researchers measure

Primary outcomes

  1. Serological response (evaluated by approved diagnostic serological tests [cryptococcosis, coccidiomycosis, and histoplasmosis]) at Weeks 2, 8, 12, and end of therapy.

    Time frame: Weeks 2, 8, 12, and end of therapy

  2. Clinical response (evaluated based on change of attributable symptoms, signs, and/or bronchoscopic abnormalities present at baseline, judged by investigators, at Weeks 1, 2, 4, 8, 12, and end of therapy) at Weeks 1, 2, 4, 8, 12, and end of therapy.

    Time frame: Weeks 1, 2, 4, 8, 12 and end of therapy

  3. Radiological response (evaluated based on all radiological abnormalities [X-ray, computed tomography scan] attributed to fungal infection compared to baseline) at Weeks 2, 8, 12, and end of therapy.

    Time frame: Weeks 2, 8, 12, and end of therapy

  4. Mycological response (evaluated by the presences of fungal pathogen by relevant specimen [microscopy or histopathology]) at Weeks 2, 8, 12, and end of therapy.

    Time frame: Weeks 2, 8, 12, and end of therapy

Secondary outcomes

  1. Global response to treatment (incorporating clinical, mycological, radiological, and serological responses as applicable) at end of therapy/Week 16.

    Time frame: End of therapy or Week 16

  2. Change from baseline in laboratory parameters at Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up.

    Time frame: Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up

  3. Change from baseline in electrocardiogram at Week 1 and end of therapy.

    Time frame: Week 1 and end of therapy

  4. Incidence of adverse events at Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up.

    Time frame: Weeks 1, 2, 4, 8, 12, end of therapy, Week 16, and follow-up

  5. Visual safety testing at Weeks 1, 8, 12, end of therapy, Week 16, and follow-up.

    Time frame: Weeks 1, 8, 12, end of therapy, Week 16, and follow-up

07

Study locations

4 sites
  • Pfizer Investigational Site
    Kaohsiung, Taiwan
  • Pfizer Investigational Site
    Taichung, 40705, Taiwan
  • Pfizer Investigational Site
    Taipei, 100, Taiwan
  • Pfizer Investigational Site
    Taipei, 114, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003 and a completion of May 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Apr 1, 2008
Start
Apr 2003
CompletionActual
May 2004
Last update
May 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00647907
Lead sponsor
Pfizer
First posted
Apr 1, 2008
Start date
Apr 2003
Completion
May 2004
Last update
May 16, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion